Pharmaceuticals, Biotechnology and Life Sciences
-GENFIT partnership expands Terns’ portfolio, adding a Phase 3 product with a complementary mechanism of action well-suited to combinations with…
Genfit, a biopharmaceutical company focused on developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, has started patient testing in the Phase 2a trial evaluating elafibranor in PBC.
GENFIT, a biopharmaceutical company focused on developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that affect the liver…
GENFIT has signed an agreement for a NASH Registry Project
GENFIT has today announced its cash and cash equivalents as at September 30, 2016
The primary objective is to determine the effect of daily oral administration of elafibranor on serum alkaline phosphatase (ALP) in these patients, based on relative change versus placebo.
French Genfit has raised €78.5 million and invests in its R&D